Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 54(3): 294-300, 2020 Mar 06.
Artículo en Zh | MEDLINE | ID: mdl-32187935

RESUMEN

Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou. Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR. Phylogenetic tree was bulit using MEGA 6.0 software. NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites. Results: A total of 1 225 nasopharyngeal specimens were collected, including 783 males and 442 females. The median (P(25), P(75)) age was 8 (3, 24) months. Among the 209 HRSV-positive cases (17.06%), 117 cases (55.98%) were HRSV-A and 92 cases (44.02%) were HRSV-B. The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years. The HRSV prevalence rate decreased with age. The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases. There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%. Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53). The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites. Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou. ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup. A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.


Asunto(s)
Infecciones por Virus Sincitial Respiratorio/epidemiología , Virus Sincitial Respiratorio Humano/genética , Virus Sincitial Respiratorio Humano/aislamiento & purificación , Niño , Niño Hospitalizado , Preescolar , China/epidemiología , Femenino , Genotipo , Humanos , Lactante , Recién Nacido , Masculino , Epidemiología Molecular , Filogenia , Infecciones por Virus Sincitial Respiratorio/diagnóstico
2.
Zhonghua Nei Ke Za Zhi ; 57(3): 216-219, 2018 Mar 01.
Artículo en Zh | MEDLINE | ID: mdl-29518868

RESUMEN

To explore the efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloid leukemia and granulocytic sarcoma (GS). Clinical outcome including hematopoietic reconstitution, transplant-related complications, survival and relapse were collected and retrospectively analyzed in 9 patients with myeloid leukemia and GS after allo-HSCT. Hematopoiesis reconstitution was achieved in all the 9 recipients. Four cases developed acute graft-versus-host disease (GVHD), and 1 with chronic GVHD. The median follow-up time after transplantation was 10(4-81) months. Only 2 cases survived, the other 7 died of relapse. The median time of relapse after transplantation was 5(3-19) months. Allo-HSCT is relatively effective treatment for patients with myeloid leukemia and GS. Relapse after transplantation remains the major factor of mortality.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda/mortalidad , Leucemia Mieloide Aguda/terapia , Sarcoma Mieloide/complicaciones , Sarcoma Mieloide/terapia , Adolescente , Adulto , Femenino , Enfermedad Injerto contra Huésped , Humanos , Leucemia Mieloide Aguda/etiología , Masculino , Recurrencia , Estudios Retrospectivos , Sarcoma Mieloide/mortalidad , Tasa de Supervivencia , Acondicionamiento Pretrasplante , Trasplante Autólogo , Trasplante Homólogo , Resultado del Tratamiento , Adulto Joven
3.
Br J Surg ; 104(1): 118-127, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27696379

RESUMEN

BACKGROUND: Liver resection is effective for hepatocellular carcinoma (HCC) exceeding the Milan criteria in selected patients. However, the benefit of anatomical resection (AR) versus non-anatomical resection (NAR) has not been clarified in this patient subgroup. This study aimed to compare outcomes between AR and NAR for HCC exceeding the Milan criteria. METHODS: Data on consecutive patients with HCC exceeding the Milan criteria who underwent liver resection with curative intent over a recent 6-year interval were extracted from a prospective single-centre HCC database and examined retrospectively. The postoperative outcomes of patients were compared before and after propensity score matching. RESULTS: Some 546 patients were included: 264 in the AR and 282 in the NAR group. In the original cohort, the AR group contained more patients with larger tumours, multiple tumours, macroscopic portal vein tumour thrombi, incomplete tumour capsules and microscopic vascular invasion. After propensity score matching, 177 pairs of patients were selected. The baseline data, including liver function and tumour burden, were similar in the matched groups. The 3-year recurrence-free survival rate was comparable between the matched NAR and AR groups (36·5 versus 28·5 per cent; P = 0·448). Similar results were observed for 3-year overall survival (57·5 versus 50·3 per cent; P = 0·385), recurrence patterns and early recurrence rates (57·6 per cent versus 59·9 per cent; P = 0·712). CONCLUSION: AR and NAR achieved favourable and similar outcomes for HCC exceeding the Milan criteria in selected patients.


Asunto(s)
Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/cirugía , Hepatectomía/métodos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/cirugía , Factores de Edad , Carcinoma Hepatocelular/mortalidad , Femenino , Humanos , Neoplasias Hepáticas/mortalidad , Masculino , Análisis por Apareamiento , Persona de Mediana Edad , Análisis Multivariante , Recurrencia Local de Neoplasia , Puntaje de Propensión , Estudios Retrospectivos , Carga Tumoral
4.
Fa Yi Xue Za Zhi ; 33(1): 25-27, 2017 Feb.
Artículo en Zh | MEDLINE | ID: mdl-29231004

RESUMEN

OBJECTIVES: To establish an automation system for detection of alcohol content in blood. METHODS: The determination was performed by automated workstation of extraction-headspace gas chromatography (HS-GC). The blood collection with negative pressure, sealing time of headspace bottle and sample needle were checked and optimized in the abstraction of automation system. The automatic sampling was compared with the manual sampling. RESULTS: The quantitative data obtained by the automated workstation of extraction-HS-GC for alcohol was stable. The relative differences of two parallel samples were less than 5%. The automated extraction was superior to the manual extraction. A good linear relationship was obtained at the alcohol concentration range of 0.1-3.0 mg/mL (r≥0.999) with good repeatability. CONCLUSIONS: The method is simple and quick, with more standard experiment process and accurate experimental data. It eliminates the error from the experimenter and has good repeatability, which can be applied to the qualitative and quantitative detections of alcohol in blood.


Asunto(s)
Cromatografía de Gases/métodos , Etanol/análisis , Etanol/sangre , Cromatografía de Gases y Espectrometría de Masas/métodos , Automatización
5.
Zhonghua Nei Ke Za Zhi ; 55(12): 927-931, 2016 Dec 01.
Artículo en Zh | MEDLINE | ID: mdl-27916046

RESUMEN

Objective: To evaluate the efficacy of unrelated donor allogeneic hematopoietic stem cell transplantation(URD allo-HSCT) for children and adolescents with severe aplastic anemia (SAA). Methods: Clinical data of 34 SAA children and adolescents undergoing allo-HSCT were retrospectively analyzed from October 2001 to October 2015. According to the source of donor, the patients were divided into matched sibling donor allo-HSCT group (MSD group) and unrelated donor group (URD group). The clinical outcome of SAA children and adolescents receiving URD allo-HSCT was assessed, and patients in MSD allo-HSCT group were enrolled as control at the same period. Results: The rate of hematopoietic reconstitution, the time of neutrophil and platelet engraftment, incidence of chimerism and graft rejection between two groups were not statistically different.The incidence of acute graft-versus-host disease (GVHD) in URD group was significantly higher than that in MSD group [42.9%(6/14) vs 10.5%(2/19), P=0.047]. The incidence of grade Ⅱ-Ⅳ acute GVHD and chronic GVHD in URD were higher than those in MSD group [21.4%(3/14) vs 5.3%(1/19), P=0.288; 35.7%(5/14) vs 5.3%(1/19), P=0.062, respectively], yet without significant difference between two groups. Other transplant-related complications including pulmonary complications, hemorrhagic cystitis, incidence of EBV and CMV reactivation and venous occlusive disease were comparable with two regimens. Estimated 5-years overall survival (OS) rate and disease free survival (DFS) rate were not statistically significant between URD group and MSD group [(84.4±6.6)% vs (89.4±7.1)%, (82.5±5.4)% vs (82.1±4.3)%; P=0.766, P=0.884, respectively]. Conclusions: By multivariate analysis, the outcome of URD allo-HSCT in SAA children and adolescent is similar to MSD allo-HSCT. It could be an alternative option as the first-line treatment for SAA children and adolescents without HLA matched sibling donors.


Asunto(s)
Anemia Aplásica/terapia , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Hermanos , Donantes de Tejidos , Donante no Emparentado , Adolescente , Anemia Aplásica/inmunología , Anemia Aplásica/mortalidad , Niño , Quimerismo , Supervivencia sin Enfermedad , Femenino , Enfermedad Injerto contra Huésped/epidemiología , Enfermedad Injerto contra Huésped/mortalidad , Trasplante de Células Madre Hematopoyéticas/mortalidad , Prueba de Histocompatibilidad , Humanos , Incidencia , Masculino , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Trasplante Homólogo/efectos adversos , Resultado del Tratamiento
6.
Epidemiol Infect ; 141(5): 1061-9, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-22827898

RESUMEN

Annual H3N2 subtype influenza outbreaks in Guangdong, China are a severe public health issue and require ongoing monitoring of emerging viral variants. The variation and evolution of haemagglutinin (HA) and neuraminidase (NA) genes of influenza isolates from Guangdong during 2007-2011 and others from GenBank were analysed using Lasergene 7.1 and MEGA 5.05, and serological analysis of antigens was determined by haemagglutination inhibition (HI). Susceptibility to antiviral drugs was correlated with genetic mutations. Phylogenetic analysis and alignment of HA and NA genes were performed on 18 Guangdong isolates and 26 global reference strains. The non-synonymous (dN) evolutionary rate of HA1 was 3.13 times that of HA2. Compared with the A/Perth/16/2009 vaccine HA gene, homologies of Guangdong isolates were between 98.8-99.7% and 98.0-98·4% in 2009 and 2010, respectively. Amino-acid substitutions were found in five epitopes of HA1 from Guangdong isolates between 2007 and 2011, especially in epitopes B (N160K) and D (K174R/N). The K189E/N/Q and T228A mutations in the receptor-binding site (RBS) occurred in the 2010 strains, which affected the antigenicity of HA1. The antigenicity of the epidemic H3N2 isolates in 2010 was somewhat different from that of A/Perth/16/2009. The Guangdong H3N2 isolates were determined to be oseltamivir-resistant with IC50 of 0.396 ± 0.085 nmol/l (n=17) and zanamivir-resistant with IC50 of 0.477 ± 0.149 nmol/l (n=18). Variations were present in epitopes B and D, two sites in the RBS and two glycosylation sites in the Guangdong H3N2 HA1 gene. The majority of the Guangdong H3N2 isolates were sensitive to oseltamivir and zanamivir. Compared to the World Health Organization 2012 vaccine strains, Guangdong H3N2 strains varied genetically and antigenically to some degree.


Asunto(s)
Antivirales/farmacología , Hemaglutininas Virales/metabolismo , Subtipo H3N2 del Virus de la Influenza A/efectos de los fármacos , Subtipo H3N2 del Virus de la Influenza A/genética , Neuraminidasa/metabolismo , Anticuerpos Antivirales , Antígenos Virales , Evolución Biológica , China/epidemiología , Brotes de Enfermedades , Farmacorresistencia Viral , Regulación Viral de la Expresión Génica/fisiología , Variación Genética , Hemaglutininas Virales/genética , Humanos , Gripe Humana/epidemiología , Gripe Humana/virología , Neuraminidasa/genética , Filogenia , ARN Viral
7.
Diabetes Obes Metab ; 14(4): 315-9, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22077482

RESUMEN

AIM: The aim of this study was to determine and compare the effect of treatment with transdermal oestrogen and phytoestrogen on insulin sensitivity and sex hormone-binding globulin (SHBG) levels in healthy postmenopausal women. METHODS: Forty-three healthy postmenopausal women aged 68 ± 7 (mean ± SD) years who were not receiving hormonal replacement therapy completed a 3 month randomized drug therapy study. The participants were randomized to one of four groups: 0.05 mg or 0.1 mg transdermal oestrogen/day, or 40 or 80 mg oral phytoestrogen (Promensil)/day insulin sensitivity was indirectly measured using the quantitative insulin sensitivity check index (QUICKI). SHBG, total testosterone, oestradiol, and fasting glucose and insulin levels for calculation of insulin sensitivity were obtained at baseline and at monthly intervals during the 3 months of therapy. RESULTS: In healthy nondiabetic postmenopausal women, the rate of change in QUICKI was significantly different between the red clover based phytoestrogen and transdermal oestrogen groups, so that after three months of therapy, QUICKI with red clover based phytoestrogen therapy was lower than that in the transdermal oestrogen group, p = 0.01. Red clover based phytoestrogen therapy was not associated with any changes in SHBG levels whereas transdermal estrogen therapy significantly increased SHBG levels, p = 0.05. CONCLUSIONS: In contrast to transdermal oestrogen therapy, oral phytoestrogen therapy does not decrease androgenicity and is associated with a decrease in insulin sensitivity. These effects are similar to those of raloxifene and consistent with phytoestrogen's selective oestrogen receptor modulator properties.


Asunto(s)
Andrógenos/metabolismo , Biomarcadores/sangre , Resistencia a la Insulina , Isoflavonas/administración & dosificación , Fitoestrógenos/administración & dosificación , Posmenopausia/metabolismo , Administración Cutánea , Administración Oral , Anciano , Anciano de 80 o más Años , Glucemia/metabolismo , Estradiol/sangre , Femenino , Humanos , Insulina/sangre , Persona de Mediana Edad , Globulina de Unión a Hormona Sexual/metabolismo , Testosterona/sangre , Reino Unido/epidemiología
8.
Zhonghua Xue Ye Xue Za Zhi ; 41(8): 666-670, 2020 Aug 14.
Artículo en Zh | MEDLINE | ID: mdl-32942821

RESUMEN

Objective: To investigate the clinicopathologic features, treatment, and prognosis in patients with Castleman disease (CD) . Methods: We retrospectively analyzed the clinicopathologic data of 59 patients for whom a diagnosis of Castleman disease was confirmed using pathological examination from October 2011 to October 2019 at the Henan Cancer Hospital. The patients were divided into the following two groups as per the following clinical classifications: unicentric CD (UCD, n=47) and multicentric CD (MCD, n=12) . Data on clinical manifestations, laboratory findings, treatment, and prognosis were analyzed. Results: There was no significant difference in the median age and the ratio of male to female between the UCD and MCD. UCD was characterized by asymptomatic enlargement of the single lymph node. The main pathological type was hyaline vascular histopathology (83.0%) . Of these, 44 patients chose surgical resection, and their prognosis was good. Treatment. MCD was characterized by multiple enlarged superficial and/or deep lymph nodes with B symptoms, weakness, and hepatosplenomegaly. Anemia, hypoproteinemia, and globulin level were increased on laboratory examinations. Plasmacyte histopathology was the main pathological type and was present in about 50.0% of the subjects. Only chemotherapy was performed for these MCD patients, followed by chemotherapy or chemotherapy followed by radiotherapy, and the efficient was 58.3% (7/12) . Conclusions: UCD, characterized by asymptomatic enlargement of the single lymph node, shows good postoperative prognosis. MCD has relatively complex clinical manifestations and poor prognosis, and optimal treatment is yet to be established.


Asunto(s)
Enfermedad de Castleman , Anemia , Femenino , Humanos , Ganglios Linfáticos , Masculino , Pronóstico , Estudios Retrospectivos
9.
Zhonghua Xue Ye Xue Za Zhi ; 40(2): 111-116, 2019 Feb 14.
Artículo en Zh | MEDLINE | ID: mdl-30831625

RESUMEN

Objective: To explore the effect of combination regimen of interferon alpha-1b, interleukin-2 and thalidomide (ITI regimen) on minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who were in hematologic remission but MRD-positive. Methods: Eighteen patients (17 from Tumor Hospital of Zhengzhou University and 1 from the First People's Hospital of Pingdingshan City) with AML admitted from July 2016 to June 2018, who were in hematologic remission but MRD-positive were treated with different doses of ITI regimen, and the MRD levels were monitored. Results: Among 18 patients who received a conventional dose of ITI regimen for 1 to 2 months, 7 patients had undetectable MRD, 3 had significant decrease in MRD levels, 3 had elevated MRD level and had hematologic recurrence. Three patients with elevated MRD level received a higher dose of ITI regimen, 2 of them turned to MRD negative and the other 1 patient had decreased MRD level. The total response rate was 72.2%, and the response rate in patients with MRD > 1.0% was 57.1% (4/7) , and that of patients with MRD < 1.0% was 81.8% (9/11) , respectively. Conclusion: The ITI regimen can reduce the MRD level of patient with AML who are in hematologic remission but MRD-positive. The therapeutic effect could be improved by a higher dose administration of ITI regimen, and therapeutic effect may be negatively correlated with MRD level before treatment.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia Mieloide Aguda , Citometría de Flujo , Humanos , Interferón-alfa , Interleucina-2 , Leucemia Mieloide Aguda/tratamiento farmacológico , Neoplasia Residual , Pronóstico , Inducción de Remisión , Talidomida
11.
Transplant Proc ; 40(5): 1710-3, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18589178

RESUMEN

The potential of embryonal day 14 (ED) fetal liver epithelial progenitor (FLEP) cells to repopulate the normal and damaged liver was studied throughout a 3-month period in syngeneic mice. In normal liver, FLEP cells proliferated and differentiated into hepatocytes after transplantation, and liver repopulation was moderate (5%-10%) after 3 months. In diethylnitrosamine-treated livers FLEP cells continued to proliferate at 3 months after transplantation; both the number and size of clusters derived from FLEP cells gradually increased throughout time. Transplanted cells proliferated and differentiated into both hepatocytes and bile ducts to produce extensive liver repopulation (30%-50%). This report showed that isolated fetal liver epithelial cells exhibit bipotential properties of stem cells, which can engraft, proliferate, and differentiate into hepatocytes and bile duct epithelial cells with high repopulation capacity in the injured liver.


Asunto(s)
División Celular/fisiología , Células Epiteliales/citología , Hígado/embriología , Células Madre/citología , Animales , Femenino , Hígado/citología , Masculino , Ratones , Ratones Endogámicos BALB C , Embarazo , Cromosoma Y
12.
Artículo en Zh | MEDLINE | ID: mdl-29365378

RESUMEN

Objective: To investigate the significance of circulating tumor cells (CTC) in squamous cell carcinoma of the head and neck (HNSCC). Methods: Twenty-four patients with HNSCC treated between October 2016 and July 2017 in our department were selected (experimental group), including 23 males and 1 females, aged 47-81 years. There were 14 cases of squamous cell carcinoma of larynx and 10 cases of hypopharynx, including I-Ⅱ stage (5 cases) and Ⅲ- Ⅳ stage (19 cases). All patients were primary and/or relapsed after treatment. Nine healthy volunteers were selected as control group. A novel in vivo capture technique (CellCellector system) was used to detect CTC. SPSS23.0 was used for statistical analysis. Results: The total capture rate of CTC in patients with HNSCC before treatment was 70.8% (17/24), with 40% (2/5) for patients at I-Ⅱ stage, and 78.9% (15/19) for patients at Ⅲ- Ⅳ stage, and was 0 in patients of control group. The total capture rate of CTC in patients with HNSCC after treatment was 50% (8/16). There was no significant correlation between CTC and age, sex, location of tumor or lymph node metastasis (P>0.05). CTC was related to tumor staging and tumor differentiation (P<0.05). The positive rate of EGFRVⅢ in CTC was 26.3% (5/19). Conclusions: The CellCollector system is a very efficient way of detecting CTC, and CTC plays an important role in the occurrence, progression and metastasis of HNSCC.


Asunto(s)
Carcinoma de Células Escamosas/secundario , Neoplasias Hipofaríngeas/patología , Neoplasias Laríngeas/patología , Células Neoplásicas Circulantes , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/química , Carcinoma de Células Escamosas/patología , Estudios de Casos y Controles , Recuento de Células , Receptores ErbB/análisis , Femenino , Humanos , Neoplasias Hipofaríngeas/química , Neoplasias Laríngeas/química , Metástasis Linfática , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Células Neoplásicas Circulantes/química , Células Neoplásicas Circulantes/patología
13.
Zhonghua Xue Ye Xue Za Zhi ; 37(8): 661-5, 2016 Aug 14.
Artículo en Zh | MEDLINE | ID: mdl-27587246

RESUMEN

OBJECTIVE: To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo- HSCT) for patients with severe aplastic anemia (SAA). METHODS: A retrospective study was conducted in 41 SAA patients received allo-HSCT from Oct. 2001 to May 2015. There were 27 males and 14 females with median age of 17(2-43) years old. Of them, 24 received matched sibling donor HSCT, 17 received unrelated donor transplantation. RESULTS: Hematopoiesis reconstitution was achieved in 38 patients (92.68%). Median time of neutrophils and platelets implantation was 16(10-57) d and 20(9-83) d in evaluable patients, respectively. Acute GVHD occurred in 13 cases, chronic GVHD in 8 cases, and graft rejection in 5 cases. Median follow-up time was 27(3- 154) months. The prospective OS for 3 years was (75.1±8.3)%. Transplantation related mortality was 24.39% (10 cases). Multivariate analysis revealed that grade Ⅱ -Ⅳ aGVHD [P=0.018, OR=27.481 (95% CI 2.377-392.636) ] and invasive fungal disease [P=0.021, OR=21.364 (95% CI 1.732- 354.185) ] were independent risk factors of OS for SAA patients after allo- HSCT. CONCLUSION: Allo- HSCT is an efficient and safe therapy for the patients with SAA, not only for patients with HLA matched sibling donor, but also for those with only HLA matched unrelated donor available. Grade Ⅱ- Ⅳ aGVHD and invasive fungal disease were associated with lower OS rate.


Asunto(s)
Anemia Aplásica/terapia , Trasplante de Células Madre Hematopoyéticas , Adolescente , Adulto , Niño , Preescolar , Femenino , Rechazo de Injerto , Enfermedad Injerto contra Huésped , Hematopoyesis , Humanos , Masculino , Estudios Prospectivos , Estudios Retrospectivos , Factores de Riesgo , Hermanos , Donantes de Tejidos , Trasplante Homólogo , Resultado del Tratamiento , Donante no Emparentado , Adulto Joven
14.
J Clin Oncol ; 15(3): 987-93, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9060537

RESUMEN

PURPOSE: A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum- and paclitaxel-based regimens. Liposomal doxorubicin was selected as a result of its superior activity against ovarian cancer xenografts relative to free doxorubicin and activity in refractory ovarian cancer patients that was noted during the phase I study. PATIENTS AND METHODS: Thirty-five consecutive patients were accrued in two institutions (22 in one and 13 in the other). All had progressive disease after either cisplatin or carboplatin and paclitaxel, or at least one platinum-based and one paclitaxel-based regimen. Patients received intravenous (I.V.) liposomal doxorubicin 50 mg/m2 every 3 weeks with a dose reduction to 40 mg/m2 in the event of grade 3 or 4 toxicities, or a lengthening of the interval to 4 weeks (and occasionally to 5 weeks) with persistence of grade 1 or 2 toxicities beyond 3 weeks. RESULTS: Nine clinical responses (one complete response [CR], eight partial responses [PRs]) were observed in 35 patients (25.7%), with seven of these having been confirmed by two consecutive computed tomographic (CT) measurements. The median progression-free survival was 5.7 months with an overall survival of 1.5 to 24+ months (median, 11 months). Although 13 patients experienced grade 3 or 4 nonhematologic skin and mucosal toxicities (either hand-foot syndrome or stomatitis), with dose modifications, the treatment was very well tolerated. Nausea that was clearly attributable to the drug, hair loss, extravasation necrosis, or decreases in ejection fraction did not occur. CONCLUSION: Liposomal doxorubicin has substantial activity against ovarian cancer refractory to platinum and paclitaxel. The responses achieved with liposomal doxorubicin were durable and maintained with minimal toxicity. This liposomal formulation should be evaluated further in combination with other drugs in less refractory patients.


Asunto(s)
Antibióticos Antineoplásicos/uso terapéutico , Doxorrubicina/uso terapéutico , Neoplasias Ováricas/tratamiento farmacológico , Anciano , Antibióticos Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Antígeno Ca-125/sangre , Cisplatino/uso terapéutico , Supervivencia sin Enfermedad , Doxorrubicina/efectos adversos , Esquema de Medicación , Portadores de Fármacos , Resistencia a Antineoplásicos , Femenino , Humanos , Infusiones Intravenosas , Liposomas , Persona de Mediana Edad , Neutropenia/inducido químicamente , Neoplasias Ováricas/inmunología , Paclitaxel/uso terapéutico , Úlcera/inducido químicamente
15.
Sci Total Environ ; 506-507: 538-45, 2015 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-25433377

RESUMEN

The contribution of polluted dust transported from local and distal sources remains poorly constrained due to their similar geophysical and geochemical properties. We sampled aerosols in three cities in northern China (Xi'an, Beijing, Xifeng) during the spring of 2009 to determine dust flux, magnetic susceptibility and elemental concentrations. Combining dust fluxes with wind speed and regional visibility records enabled to differentiate between dust transported from long range and derived from local sources, while the combination of magnetic susceptibility and enrichment factors (EF) of heavy metals (Pb, Zn) allowed to distinguish natural aerosols from polluted ones. Our results indicate that polluted dust from long-range transport became a major end member of urban dust aerosols. Human settlements as its potential sources were confirmed by a pollutant enriched regional dust event originating from populated areas to the south as inferred by back trajectory modeling, implying their non-point source nature of dust pollution.


Asunto(s)
Aerosoles/análisis , Contaminantes Atmosféricos/análisis , Contaminación del Aire/estadística & datos numéricos , Polvo/análisis , Monitoreo del Ambiente , China , Metales Pesados/análisis , Viento
16.
Hepatogastroenterology ; 48(42): 1701-4, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11813604

RESUMEN

BACKGROUND/AIMS: To evaluate clinical significance of portal hemodynamic investigation in prediction of hepatic functional reserve in patients with hepatocellular carcinoma undergoing operative treatment. METHODOLOGY: By using the color Doppler velocity profile technique, preoperative portal hemodynamic status was assessed in 29 patients with hepatocellular carcinoma treated surgically, including 15 segmentectomies, 6 hemihepatectomies and 8 transarterial chemoembolizations. Forty-six normal volunteers were taken as control. Comparison of preoperative portal hemodynamics between patients recovering from operation smoothly (tolerant subgroup) and those with major complications or death (intolerant subgroup) was done, and discriminant analysis was employed to identify the cut-off value for significant parameters that maximally separate the tolerant subgroup from the intolerant subgroup. RESULTS: In the portal trunk, CSVmax (maximum cross-sectional mean velocity) was significantly lower in the hepatocellular carcinoma group compared with the normal group (P < 0.01); flow volume was not obviously different between the two groups; congestion index was markedly higher in the hepatocellular carcinoma group than that of the normal group (P < 0.05). In the splenic vein, CSVmax and congestion index was not obviously different between the hepatocellular carcinoma and the normal groups; flow volume was significantly higher in the hepatocellular carcinoma group than that of the normal group (P < 0.05). In the hepatocellular carcinomas, twenty-three patients recovered smoothly from the operation and the remaining 6 had severe complications or death. Tolerant subgroup had a significantly higher preoperative CSVmax and flow volume and lower congestion index of the portal trunk compared with the intolerant subgroup (all P < 0.01). Discriminant analysis revealed that portal trunk CSVmax > 13.50 cm/s and flow volume > 12.13 mL/min/kg could predict tolerance for surgery, with an accuracy of 82.7% and 89.7%, respectively. CONCLUSIONS: The results suggest that preoperative portal hemodynamic status in hepatocellular carcinomas had a close correlation with hepatic functional reserve, and CSVmax and flow volume of portal trunk might become valuable predictive parameters.


Asunto(s)
Carcinoma Hepatocelular/fisiopatología , Neoplasias Hepáticas/fisiopatología , Hígado/fisiopatología , Sistema Porta/fisiopatología , Adulto , Anciano , Velocidad del Flujo Sanguíneo , Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/cirugía , Femenino , Hemodinámica , Humanos , Pruebas de Función Hepática , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Ultrasonografía Doppler en Color/métodos
17.
Zhonghua Zhong Liu Za Zhi ; 14(6): 449-51, 1992 Nov.
Artículo en Zh | MEDLINE | ID: mdl-1338987

RESUMEN

We performed two-stage resection for thirteen patients with advanced hepatocellular carcinoma from January 1987 to January 1991. All patients underwent various surgical therapies prior to resection which included gauze packing hemostasis in 1 case, hyperthermia plus radiotherapy in 1, hepatic arterial ligation in 2, operative hepatic arterial embolization in 1, and transcatheter embolization in 8. The median interval between the first therapy and tumor resection was 54 days with a range of 29-769 days and the median diameter of tumors decreased from 10.5 cm to 7.5 cm. The majority of procedures on two-stage resection were irregular hepatectomy or lobectomy under occlusion of porta hepatis. Regular hepatectomies were done in 4 cases. Pathological examination showed complete coagulation necrosis in 3 specimens. However, in the others were still found residual viable tumor cells outside or beneath the tumor capsule with varying degrees of necrosis within the tumors. Survival periods of the patients who received two-stage resection were from 4 months to 4 years except 2 operative death. The significance, possibility as well as methods of two-stage resection were discussed.


Asunto(s)
Carcinoma Hepatocelular/cirugía , Neoplasias Hepáticas/cirugía , Adulto , Carcinoma Hepatocelular/terapia , Terapia Combinada , Embolización Terapéutica , Femenino , Hepatectomía/métodos , Humanos , Neoplasias Hepáticas/terapia , Masculino , Persona de Mediana Edad
18.
Zhonghua Wai Ke Za Zhi ; 28(4): 206-8, 251-2, 1990 Apr.
Artículo en Zh | MEDLINE | ID: mdl-2379435

RESUMEN

Seventy transcatheter hepatic artery chemoembolizations with an emulsion containing iodized oil, adriamycin and 5-Fu were undertaken for the treatment of primary liver cancer in 58 patients and secondary liver cancer in 2 patients. The oil emulsion was selectively lodged in tumor vessels and small daughter nodules not detected by angiography or computed tomography prior to the chemoembolization Following the procedure, liver tumors appeared as areas of markedly high density on CT Hepatectomy performed on 3 of these cases following the chemoembolization found complete necrosis of the tumor in 2. The cumulative one-and two-year survival rates were 35.5% and 24.1% respectively. The results we have got indicate that the chemoembolization is a useful palliative measure for the treatment of hepatic neoplasms.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Embolización Terapéutica , Neoplasias Hepáticas/terapia , Adulto , Anciano , Doxorrubicina/administración & dosificación , Embolización Terapéutica/métodos , Femenino , Fluorouracilo/administración & dosificación , Arteria Hepática , Humanos , Masculino , Persona de Mediana Edad
19.
Zhonghua Wai Ke Za Zhi ; 32(11): 659-61, 1994 Nov.
Artículo en Zh | MEDLINE | ID: mdl-7774402

RESUMEN

This paper introduced a technique of portal vein embolization by injection of ethanol via fine needle under guidance of angio-echography. First introportal ethanol injection were done in 28 dogs to evaluate its embolic efficacy and safety. The result showed if a dose of injected ethanol was chosen properly, expected embolization could be obtained with slight toxicity to hepatic parenchyma and function. For clinical application, selective portal vein puncture was percutaneous transhepatic under echo guidance. Ultrasound angiography by injecting carbon dioxide (CO2) into portal vein was introduced initially. After confirmed that the injected branch was that supplied the tumor and there was no retrograde overflow of portal blood, ethanol was injected at a dose no more than 10ml. Eighteen patients with hepatocellular carcinoma and underlying liver cirrhosis underwent the procedure preoperatively. Of 14 cases who received hepatectomies, portal vein embolization developed in 12. Since the procedure was guided by angio-echography it could be used for indicated cases with satisfactory embolic effect and not harmful to liver. The procedure had advantages of simple manipulation and made selective embolization easier compared to interventional transcatheter portal vein embolization.


Asunto(s)
Carcinoma Hepatocelular/terapia , Embolización Terapéutica/métodos , Neoplasias Hepáticas/terapia , Ultrasonografía Intervencional , Adulto , Animales , Carcinoma Hepatocelular/complicaciones , Perros , Etanol/administración & dosificación , Femenino , Humanos , Cirrosis Hepática/complicaciones , Neoplasias Hepáticas/complicaciones , Masculino , Persona de Mediana Edad , Agujas , Vena Porta
20.
Clin Transl Oncol ; 16(8): 753-60, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24338510

RESUMEN

BACKGROUND: Immunotherapy is an effective method for preventing metastasis and recurrence of carcinoma. Hepatocellular carcinoma (HCC) is a common malignancy with a high rate of recurrence, and has not successfully been introduced to immunotherapy. METHODS: Peripheral blood mononuclear cells were isolated from whole blood of HCC patients and stimulated to transform into dendritic cells (DCs). These DCs were then transfected with RNA extracted from HepG-2 hepatoma cells to induce expression of specific antigens. RESULTS: The transfected DCs stimulated T lymphocytes to produce cytotoxic T lymphocytes, which specifically attacked HepG-2 cells. Injection of T lymphocytes from HCC patients and transfected DCs into severe combined immunodeficiency mice limited the growth of HepG-2 tumors. CONCLUSION: A specific immune response against hepatoma can be generated in vivo by administering DCs transfected with RNA from a specific tumor. This method may have therapeutic application in humans to reduce recurrence of HCC.


Asunto(s)
Vacunas contra el Cáncer/inmunología , Carcinoma Hepatocelular/inmunología , Células Dendríticas/trasplante , Neoplasias Hepáticas/inmunología , ARN Neoplásico/inmunología , Animales , Antígenos de Neoplasias/inmunología , Células Dendríticas/inmunología , Citometría de Flujo , Humanos , Técnicas In Vitro , Ratones , Linfocitos T Citotóxicos/inmunología , Transfección , Ensayos Antitumor por Modelo de Xenoinjerto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA